Moderate to Severe Plaque Psoriasis Market to Expand Rapidly with Advancing Pipeline and Increasing Treatment Adoption by 2032 - DelveInsight

DelveInsight's "Moderate to Severe Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Moderate to Severe Plaque Psoriasis, historical and forecasted epidemiology as well as the Moderate to Severe Plaque Psoriasis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Moderate to Severe Plaque Psoriasis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Moderate to Severe Plaque Psoriasis Market Forecast
https://www.delveinsight.com/sample-request/moderate-to-severe-plaque-psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the Moderate to Severe Plaque Psoriasis Market Report:
• The Moderate to Severe Plaque Psoriasis market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
• In July 2026, The U.S. Food and Drug Administration (FDA) has approved risankizumab-rzaa (Skyrizi; AbbVie) for the treatment of moderate to severe plaque psoriasis in children aged 6 years and older who are eligible for systemic therapy or phototherapy, as well as for pediatric patients aged 6 years and older with active psoriatic arthritis. The approval also includes a new 55 mg prefilled syringe to enable weight-based dosing for patients weighing less than 40 kg. With this approval, Skyrizi becomes the first and only IL-23 inhibitor authorized in the United States for pediatric patients aged 6 years and older weighing under 40 kg with plaque psoriasis or psoriatic arthritis.
• In July 2026, Clinical trial findings showed that the biosimilar ABP 654 maintained comparable efficacy, safety, pharmacokinetics, and immunogenicity even after patients underwent multiple switches between ABP 654 and the reference ustekinumab product. The randomized, double-blind study assessed adults with moderate to severe plaque psoriasis who alternated three times between ABP 654 (ustekinumab-auub; marketed as Wezlana/Wezenla) and Stelara. The results demonstrated that repeated switching did not negatively affect treatment outcomes, supporting the biosimilar's interchangeability with the reference biologic. These findings, published in the British Journal of Dermatology, contributed to the FDA's October 2023 approval of ABP 654 as the first interchangeable ustekinumab biosimilar available in the United States.
• In March 2026, Alumis Inc., a late-stage biopharmaceutical firm focused on developing next-generation targeted treatments for immune-mediated conditions, announced that findings from its Phase 3 ONWARD program assessing envudeucitinib an oral, next-generation tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis-have been selected for a late-breaking oral presentation. Additionally, a new biomarker analysis from the Phase 2 STRIDE trial of envudeucitinib has been accepted as an e-poster at the American Academy of Dermatology Annual Meeting 2026, scheduled to take place March 27-31, 2026, in Denver, Colorado.
• In May 2022, Deucravacitinib treatment for adult patients with moderate to severe plaque psoriasis has been shown to have lasting efficacy and a consistent safety profile, according to two-year data from the POETYK PSO long-term extension (LTE) experiment released by Bristol Myers Squibb. Clinical efficacy persisted for up to two years after starting deucravacitinib treatment, with response rates of 77.7% and 58.7% for static Physicians Global Assessment (sPGA) 0/1 (clean/almost clear skin) and psoriasis area and severity index (PASI) 75, respectively, at Week 60 in the LTE.
• In April 2022, Amgen released the preliminary findings of a Phase 3 research comparing ABP 654 to STELARA® (ustekinumab) in treating adult patients with moderate to severe plaque psoriasis. The primary efficacy endpoint of the research was achieved, showing no clinically significant differences between ABP 654 and STELARA
• A study of European psoriasis patients revealed, according to the WHO'S Global Report on Psoriasis, that the overall impact of psoriasis grew along with the severity of the condition. 15% of individuals with mild psoriasis, 23% with moderate psoriasis, and 51% with severe psoriasis reported having a serious psoriasis issue
• Key Moderate to Severe Plaque Psoriasis Companies: Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant, Dr. Reddy's Laboratories, Arcutis Biotherapeutics, Affibody, Merck, Can-Fite BioPharma, UCB Biopharma, Nimbus Lakshmi, Inc., Biocad, Samsung Bioepis Co., Ltd., Idera Pharmaceuticals, Inc., Suzhou Zelgen Biopharmaceuticals, Kyowa Kirin Korea Co., Ltd., AbbVie, Hangzhou Highlightll Pharmaceutical, Meiji Pharma USA Inc., Janssen Research & Development, and others
• Key Moderate to Severe Plaque Psoriasis Therapies: bimekizumab, NDI-034858, SCD-044, BCD-085 Q2W, Stelara® (Ustekinumab), IMO-3100, Jaktinib, KHK4827, ABT-874, TLL018, ME3183, JNJ-77242113, and others
• The Moderate to Severe Plaque Psoriasis epidemiology based on gender analyzed that males are slightly more affected with Moderate to Severe Plaque Psoriasis as compared to females
• The Moderate to Severe Plaque Psoriasis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Moderate to Severe Plaque Psoriasis pipeline products will significantly revolutionize the Moderate to Severe Plaque Psoriasis market dynamics.

Moderate to Severe Plaque Psoriasis Overview
An immune-mediated chronic skin condition called psoriasis causes skin cells to divide up to ten times more quickly than they normally would. Patches of severely itchy, thickly red skin with silvery scales are the result of psoriasis. Patches can also affect other areas (fingernails, toenails, and mouth), however they are most commonly observed on the elbows, knees, scalp, lower back, cheeks, palms, and soles of the feet. Plaque psoriasis is the most prevalent kind of psoriasis, accounting for around 80% of all cases.

Get a Free sample for the Moderate to Severe Plaque Psoriasis Market Report:
https://www.delveinsight.com/report-store/moderate-to-severe-plaque-psoriasis-market

Moderate to Severe Plaque Psoriasis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Moderate to Severe Plaque Psoriasis Epidemiology Segmentation:
The Moderate to Severe Plaque Psoriasis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Moderate to Severe Plaque Psoriasis
• Prevalent Cases of Moderate to Severe Plaque Psoriasis by severity
• Gender-specific Prevalence of Moderate to Severe Plaque Psoriasis
• Diagnosed Cases of Episodic and Chronic Moderate to Severe Plaque Psoriasis

Download the report to understand which factors are driving Moderate to Severe Plaque Psoriasis epidemiology trends @ Moderate to Severe Plaque Psoriasis Epidemiology Forecast
https://www.delveinsight.com/sample-request/moderate-to-severe-plaque-psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Moderate to Severe Plaque Psoriasis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Moderate to Severe Plaque Psoriasis market or expected to get launched during the study period. The analysis covers Moderate to Severe Plaque Psoriasis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Moderate to Severe Plaque Psoriasis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Moderate to Severe Plaque Psoriasis Therapies and Key Companies
• bimekizumab: UCB Biopharma
• NDI-034858: Nimbus Lakshmi, Inc.
• SCD-044: Sun Pharmaceutical
• BCD-085 Q2W: Biocad
• Stelara® (Ustekinumab): Samsung Bioepis Co., Ltd.
• IMO-3100: Idera Pharmaceuticals, Inc.
• Jaktinib: Suzhou Zelgen Biopharmaceuticals
• KHK4827: Kyowa Kirin Korea Co., Ltd.
• ABT-874: AbbVie
• KHK4827: Kyowa Kirin Co., Ltd.
• TLL018: Hangzhou Highlightll Pharmaceutical
• ME3183: Meiji Pharma USA Inc.
• JNJ-77242113: Janssen Research & Development

Discover more about therapies set to grab major Moderate to Severe Plaque Psoriasis market share @ Moderate to Severe Plaque Psoriasis Treatment Market
https://www.delveinsight.com/sample-request/moderate-to-severe-plaque-psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Moderate to Severe Plaque Psoriasis Market Drivers
• Rising Prevalence of Psoriasis: The increasing global burden of moderate to severe plaque psoriasis, coupled with greater awareness and improved diagnosis, is expanding the eligible patient population for advanced therapies.
• Growing Adoption of Biologics and Targeted Therapies: Strong uptake of IL-17, IL-23, TNF-α inhibitors, and emerging oral targeted therapies is driving market growth by offering superior efficacy and long-term disease control.
• Robust Clinical Pipeline: Continuous development of next-generation biologics, biosimilars, and novel immunomodulators is expected to strengthen the treatment landscape and improve patient outcomes.
• Favorable Reimbursement and Healthcare Access: Expanded insurance coverage and supportive reimbursement policies in developed markets are increasing patient access to premium psoriasis therapies.
• Advancements in Personalized Medicine: Biomarker research and precision medicine approaches are enabling more tailored treatment strategies, improving therapeutic effectiveness and patient adherence.

Moderate to Severe Plaque Psoriasis Market Barriers
• High Cost of Advanced Therapies: Biologics and other targeted treatments remain expensive, creating affordability challenges and limiting access in many regions.
• Patent Expirations and Biosimilar Competition: The introduction of biosimilars is increasing pricing pressure on branded biologics, impacting market revenues.
• Long-Term Safety and Treatment Switching: Concerns regarding adverse events, immunogenicity, and loss of therapeutic response may necessitate treatment switching and affect patient outcomes.
• Stringent Regulatory Requirements: Extensive clinical evidence and post-marketing safety monitoring increase development costs and extend approval timelines for new therapies.
• Limited Access in Emerging Markets: Inadequate healthcare infrastructure, lower reimbursement coverage, and delayed diagnosis continue to restrict the adoption of advanced psoriasis treatments in developing countries.

Scope of the Moderate to Severe Plaque Psoriasis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Moderate to Severe Plaque Psoriasis Companies: Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant, Dr. Reddy's Laboratories, Arcutis Biotherapeutics, Affibody, Merck, Can-Fite BioPharma, UCB Biopharma, Nimbus Lakshmi, Inc., Biocad, Samsung Bioepis Co., Ltd., Idera Pharmaceuticals, Inc., Suzhou Zelgen Biopharmaceuticals, Kyowa Kirin Korea Co., Ltd., AbbVie, Hangzhou Highlightll Pharmaceutical, Meiji Pharma USA Inc., Janssen Research & Development, and others
• Key Moderate to Severe Plaque Psoriasis Therapies: bimekizumab, NDI-034858, SCD-044, BCD-085 Q2W, Stelara® (Ustekinumab), IMO-3100, Jaktinib, KHK4827, ABT-874, TLL018, ME3183, JNJ-77242113, and others
• Moderate to Severe Plaque Psoriasis Therapeutic Assessment: Moderate to Severe Plaque Psoriasis current marketed and Moderate to Severe Plaque Psoriasis emerging therapies
• Moderate to Severe Plaque Psoriasis Market Dynamics: Moderate to Severe Plaque Psoriasis market drivers and Moderate to Severe Plaque Psoriasis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Moderate to Severe Plaque Psoriasis Unmet Needs, KOL's views, Analyst's views, Moderate to Severe Plaque Psoriasis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.